Literature DB >> 29923753

Biomarkers in early-phase trials: fundamental issues.

Laura M Yee1, Tracy G Lively1, Lisa M McShane1.   

Abstract

Biomarkers are frequently being included in early-phase clinical trials. This article is meant to introduce clinical investigators to the fundamentals of choosing a biomarker test for use in an early phase trial. Steps to consider are briefly outlined including defining the role of the biomarker in the early phase trial; selecting a fit-for-purpose biomarker test and laboratory; describing the test procedures; carrying out analytical validation testing appropriate for the research objectives and the risk involved in the trial; implementing the test in the trial; and planning for the future. Examples illustrate analytical validation approaches in the context of typical biomarker roles. The importance of collaboration between clinical investigators and laboratory researchers is emphasized.

Entities:  

Keywords:  analytical validation; biomarkers; clinical trials; drug development; early-phase trials

Mesh:

Substances:

Year:  2018        PMID: 29923753      PMCID: PMC6123886          DOI: 10.4155/bio-2018-0006

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.695


  22 in total

Review 1.  Sharing gene expression data: an array of options.

Authors:  D H Geschwind
Journal:  Nat Rev Neurosci       Date:  2001-06       Impact factor: 34.870

2.  Reporting recommendations for tumor marker prognostic studies.

Authors:  Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark
Journal:  J Clin Oncol       Date:  2005-09-19       Impact factor: 44.544

3.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

Review 4.  Analytical and clinical evaluation of biomarkers assays: when are biomarkers ready for prime time?

Authors:  Gene A Pennello
Journal:  Clin Trials       Date:  2013-08-27       Impact factor: 2.486

5.  A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.

Authors:  Jacqueline Anne Hall; Roberto Salgado; Tracy Lively; Fred Sweep; Anna Schuh
Journal:  Lancet Oncol       Date:  2014-04       Impact factor: 41.316

6.  Clinical Laboratory Improvement Amendments of 1988 (CLIA); Fecal Occult Blood (FOB) Testing. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2017-10-20

7.  Burdensome Research Procedures in Trials: Why Less Is More.

Authors:  Jonathan Kimmelman; David B Resnik; Jeffrey Peppercorn; Mark J Ratain
Journal:  J Natl Cancer Inst       Date:  2017-04-01       Impact factor: 13.506

Review 8.  Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.

Authors:  J Cummings; F Raynaud; L Jones; R Sugar; C Dive
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

Review 9.  Effective incorporation of biomarkers into phase II trials.

Authors:  Lisa M McShane; Sally Hunsberger; Alex A Adjei
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

10.  Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.

Authors:  Lisa M McShane; Margaret M Cavenagh; Tracy G Lively; David A Eberhard; William L Bigbee; P Mickey Williams; Jill P Mesirov; Mei-Yin C Polley; Kelly Y Kim; James V Tricoli; Jeremy M G Taylor; Deborah J Shuman; Richard M Simon; James H Doroshow; Barbara A Conley
Journal:  BMC Med       Date:  2013-10-17       Impact factor: 11.150

View more
  10 in total

1.  Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials.

Authors:  Laura M Yee; Lisa M McShane; Boris Freidlin; Margaret M Mooney; Edward L Korn
Journal:  Cancer J       Date:  2019 Jul/Aug       Impact factor: 3.360

Review 2.  Developmental Pharmacodynamics and Modeling in Pediatric Drug Development.

Authors:  Laurie S Conklin; Eric P Hoffman; John van den Anker
Journal:  J Clin Pharmacol       Date:  2019-09       Impact factor: 3.126

3.  External Quality Assessment of Maternal Serum Levels of Alpha-Fetoprotein, Free Beta-Human Chorionic Gonadotropin, and Unconjugated Estriol in Detecting Down Syndrome and Neural Tube Defects in the Second Trimester of 87 Maternal Serum Samples, Based on 105-139 Days.

Authors:  Yiming Chen; Yijie Chen; Yezhen Shi; Wenwen Ning; Xiaoying Wang; Liyao Li; Huimin Zhang
Journal:  Med Sci Monit       Date:  2022-04-13

Review 4.  Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials.

Authors:  Danielle Johnson; Dyfrig Hughes; Munir Pirmohamed; Andrea Jorgensen
Journal:  J Pers Med       Date:  2019-09-01

Review 5.  Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders.

Authors:  Maurits F J M Vissers; Jules A A C Heuberger; Geert Jan Groeneveld
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

Review 6.  Biomarkers in oral immunotherapy.

Authors:  Haitao Zhu; Kaifa Tang; Guoqiang Chen; Zhongwei Liu
Journal:  J Zhejiang Univ Sci B       Date:  2022 Sept 15       Impact factor: 5.552

7.  Evaluation of electrolyte element composition in human tissue by laser-induced breakdown spectroscopy (LIBS).

Authors:  Philipp Winnand; K Olaf Boernsen; Georgi Bodurov; Matthias Lammert; Frank Hölzle; Ali Modabber
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

8.  Characterizing the electrophysiological abnormalities in visually reviewed normal EEGs of drug-resistant focal epilepsy patients.

Authors:  Yogatheesan Varatharajah; Brent Berry; Boney Joseph; Irena Balzekas; Tal Pal Attia; Vaclav Kremen; Benjamin Brinkmann; Ravishankar Iyer; Gregory Worrell
Journal:  Brain Commun       Date:  2021-05-14

Review 9.  Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities.

Authors:  Sarah J Tabrizi; Michael D Flower; Christopher A Ross; Edward J Wild
Journal:  Nat Rev Neurol       Date:  2020-08-14       Impact factor: 42.937

Review 10.  Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation.

Authors:  Nikolaos Batis; Jill M Brooks; Karl Payne; Neil Sharma; Paul Nankivell; Hisham Mehanna
Journal:  Adv Drug Deliv Rev       Date:  2021-06-27       Impact factor: 15.470

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.